Air Traffic Control Equipment Market 2014

Air Traffic Control Equipment Market 2014
WORLD AIR TRAFFIC CONTROL EQUIPMENT MARKET TO BE WORTH US$3,849M IN 2014 London, UK. 25th SEPTEMBER 2014: Visiongain values the global air traffic control equipment market at US$3,849m in 2014. This will be driven by international, regional and national demand and programmes to modernise and upgrade their air traffic control and management equipment and systems ...

JACKSON SQUARE JOINS ALLERGAN INVESTORS AGAINST SALIX BID

Allergan investors voicing concerns that the maker of Botox may pursue a costly acquisition to fend off a $54 billion takeover bid by Valeant, have been joined by Jackson Square Partners, Bloomberg reports. Allergan’s board should not complete any deal before a meeting with shareholders on 18th December, said Jeff Van Harte, chairman and CIO ...

SEATTLE GENETICS AND TAKEDA’S CANCER DRUG MEETS MAIN TRIAL GOAL

Seattle Genetics and Takeda Pharmaceutical said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer, Reuters reports. Consolidation therapy kills any cancer cells that may be left in the body after initial therapy. Patients who received the drug, Adcetris, immediately after ...

EU AGENCY BACKS NOVARTIS’ SIGNIFOR DRUG

A committee of the EMA has recommended Novartis drug Signifor for EU approval to treat a rare hormonal disorder, the Swiss drug maker said 26th September, Reuters reports. The drug, used to treat adults with acromegaly for whom surgery is not an option, was approved by the EMA’s Committee for Medicinal Products for Human Use ...

EMA RECOMMENDS ASTRAZENECA’S MOVENTIG

A drug for the treatment of opioid-induced constipation, MOVENTIG, from AstraZeneca, was recommended for approval by European regulators on 26th September, Reuters reports. Recommendations for marketing approval by the agency’s Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the EC within a couple of months. The drug is used for treating ...

SALIX’S CONSTIPATION DRUG SECURES APPROVAL FOR EXPANDED USE

Salix Pharma has said the FDA has approved an expanded use of its constipation treatment, Reuters reports. The injection, Relistor, has now been approved for use in patients on opioids for chronic pain unrelated to cancer, the company said on 29th September. Relistor was first approved in 2008 to treat opioid-induced constipation in severely ill ...

OVER 700 BIOSIMILARS NOW IN DEVELOPMENT WORLDWIDE

More than 700 follow-on biologic therapies are currently in development, and they are expected to account for around a quarter of the $100 billion-worth of sales stemming from off-patent biologic drugs by the end of this decade, according to new research, pharmatimes.com reports. It is rare to see a new business segment emerge in any ...

AMAG PHARMA ENTERS WOMEN’S HEALTH BUSINESS WITH $675MN DEAL

Amag Pharma has entered the women’s healthcare business by acquiring privately held Lumara Health for $675 million in its biggest deal ever, sending its shares up as much as 23 per cent to a four-year high, Reuters reports. The cash and stock deal gives Amag access to Lumara’s Makena, the only approved product designed to ...

ALLERGAN SHAREHOLDER T. ROWE SAYS NO DEALS WITHOUT VOTE

Allergan’s third-largest shareholder, T. Rowe Price Group, said it is concerned about the drug maker’s governance and urged that any deal affecting a proposed acquisition by Valeant be put to a vote of investors, Bloomberg reports. Allergan, the maker of the anti-wrinkle treatment Botox, was said to be in talks to buy Salix Pharma in ...

BAXTER PLANS TO OPEN R&D CENTRE IN MASSACHUSETTS FOR BAXALTA SPINOFF

Baxter announced 29th September that it would form a research and development center in Cambridge, Massachusetts, for the biopharma business it expects to spin off as a separate company in mid-2015, Reuters reports. The new company, to be called Baxalta, is expected to employ about 400 people in research and development at the Cambridge facility, ...